Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | STS | P08842 | 2/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763003 | 1.00 | CCR1 (0.40) | CCR1MAPK1HSD17B10NAAACXCL8 | |
| SCHEMBL6758395 | 0.90 | CCR1 (0.50) | CCR1NAAACXCL8STSEPHX2 | |
| SCHEMBL6156889 | 0.90 | CCR1 (0.50) | CCR1NAAACXCL8STSEPHX2 | |
| SCHEMBL6156882 | 0.90 | CCR1 (0.50) | CCR1NAAACXCL8STSEPHX2 | |
| SCHEMBL6762783 | 0.86 | MAPK1 (0.40) | CCR1MAPK1HSD17B10NAAAMEN1 | |
| SCHEMBL6762776 | 0.86 | MAPK1 (0.40) | CCR1MAPK1HSD17B10NAAAMEN1 | |
| SCHEMBL6761307 | 0.86 | CCR1 (0.42) | CCR1MAPK1HSD17B10NAAAMEN1 | |
| SCHEMBL6761310 | 0.86 | CCR1 (0.42) | CCR1MAPK1HSD17B10NAAAMEN1 | |
| SCHEMBL6761869 | 0.85 | MAPK1 (0.38) | CCR1MAPK1HSD17B10NAAAMEN1 | |
| SCHEMBL6760357 | 0.84 | MAPK1 (0.51) | CCR1MAPK1HSD17B10NAAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | claimed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | CCR1 1/4885MAPK1 438/4885HSD17B10 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.